IDiyas

For the Inventor, By the Inventor

Lachen, Switzerland

Octapharma Ag


USPTO Granted Patents = 52



Trademarks = 27

Forward Citations = 173

Loading Chart...
Loading Chart...

112 inventors (with patents filed for the assignee):

goldMedal Stefan Winge (14 out of 20 patents)

silverMedal Werner Gehringer (7 out of 7 patents)

bronzeMedal Petra Schulz (6 out of 6 patents)

4.  Djuro Josic (6 out of 9 patents)

5.  Monika Stadler (5 out of 5 patents)

6.  Horst Schwinn (5 out of 16 patents)

7.  Rainer Pape (4 out of 4 patents)

8.  Karin Ahrer (4 out of 4 patents)

9.  Waltraud Kaar (4 out of 4 patents)

10.  Christoph Kannicht (4 out of 4 patents)

11.  Gustav Gilljam (4 out of 4 patents)

12.  Gerhard Gruber (4 out of 4 patents)

13.  Jürgen Römisch (3 out of 3 patents)

14.  Guido Kohla (3 out of 3 patents)

15.  Barbara Solecka-Witulska (3 out of 3 patents)


Core Competencies:
FX Activation
Immunoglobulin Composition
Glycosylated VWF Fusion Proteins
C1-Esterase Inhibitor
Polypeptides Modulating SIGLEC
Fibrinogen Production
Factor VIII Separation
Recombinant Human Proteins
Virus Inactivation Methods
Protein Purification
Hemostatically Active Preparations
Wound Healing Factors

52 patents:

1. 12274738 - FX activation process and its use in the preparation of a FXa composition (2025-04-14),
2. 12233126 - High concentration immunoglobulin composition for pharmaceutical application (2025-02-25),
3. 12171808 - Glycosylated VWF fusion proteins with improved pharmacokinetics (2024-12-24),
4. 12083171 - C1-esterase inhibitor preparation (2024-09-10),
5. 11738069 - Polypeptides modulating SIGLEC dependent immune responses (2023-08-29),
6. 11713458 - Means and methods for modifying multiple alleles (2023-08-01),
7. 11401300 - Process for production of fibrinogen and fibrinogen produced thereby (2022-08-02),
8. 11383002 - Plasma-based films and methods for making and using the same (2022-07-12),
9. 11383001 - Plasma-based films and methods for making and using the same (2022-07-12),
10. 11191833 - High concentration immunoglobulin composition for pharmaceutical application (2021-12-07),
11. 11013789 - Polypeptides modulating SIGLEC dependent immune responses (2021-05-25),
12. 10889630 - Method of separating Factor VIII from blood products (2021-01-12),
13. 10822393 - Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG (2020-11-03),
14. 10640548 - Method for inactivation/removal of coagulation factors by precipitation (2020-05-05),
15. 10626431 - Method for improved isolation of recombinantly produced proteins (2020-04-21),
Octapharma AG is a Swiss-based global company focused on the development, production, and distribution of plasma-derived and recombinant therapeutic proteins. With more than 35 years of experience, Octapharma has become a leader in the field of human proteins. The company's mission is to improve the lives of patients worldwide by providing high-quality and innovative healthcare solutions. Octapharma operates in over 115 countries and employs around 10,000 people. Their product portfolio includes treatments for bleeding disorders, immune deficiencies, critical care, and more.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
52 Patents

#1 in Lachen

#268 in Switzerland

#13,143 in the World

...
Lachen, Switzerland

Octapharma Ag

Forward Citations = 173

112 inventors:

goldMedal Stefan Winge (14 out of 20 patents)

silverMedal Werner Gehringer (7 out of 7 patents)

bronzeMedal Petra Schulz (6 out of 6 patents)

4.  Djuro Josic (6 out of 9 patents)

5.  Monika Stadler (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com
Loading…